IgA Nephropathy Secondary to Ipilimumab Use
Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Karger Publishers
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b42 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|